Cancer News and Research

Latest Cancer News and Research

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Researchers from Boston University School of Medicine (BUSM) have found that patients with node negative T3 and T4 non-small lung cancer who underwent chemotherapy before surgery had more than three times the survival rate than patients who only underwent surgery. These findings currently appear on-line in the Journal of Thoracic and Cardiovascular Surgery.

1 Mar 2011

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Sanfilippo disease is a rare disorder caused by the failure of enzymes to break down specific kinds of complex carbohydrates, resulting in their accumulation in cells and often severe physical and neurological problems - and sometimes early death.

1 Mar 2011

Despite absence of Medicare coverage, hospital use of CTC is on the rise: Study

Despite the absence of Medicare coverage, hospital use of computed tomographic colonography, commonly referred to as virtual colonoscopy, is on the rise, according to a study in the March issue of the Journal of the American College of Radiology.

1 Mar 2011

HP announces innovative drug research application for its inkjet technology

HP today announced an innovative drug research application for its inkjet technology that enables pharmaceutical companies to more efficiently develop better drugs through vastly more precise dispensing of dosages.

1 Mar 2011

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).

1 Mar 2011

Cancer drug may help combat flu

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.

1 Mar 2011

Social networking websites can increase risky sexual behaviors in homeless youth: New study

A new UCLA AIDS Institute study suggests that the use of social networking websites by homeless youth can lead to an increase in risky sexual behaviors. But interestingly, homeless kids who used these sites were also more likely to have been tested for sexually transmitted infections and to be better informed about preventing such infections and HIV.

1 Mar 2011

Two genes linked to binge drinking

University of Maryland School of Medicine researchers have identified two genes associated with binge drinking that may open doors to new, more effective treatments for excessive alcohol drinking. The scientists found that manipulating two receptors in the brain, GABA receptors and toll-like receptor 4 (TLR4), "caused profound reduction" of binge drinking for two weeks in rodents that had been bred and trained to drink excessively. The study was published online the week of Feb. 28 in the journal the Proceedings of the National Academy of Sciences.

1 Mar 2011

Genzyme introduces new global grant program to support LSD patient community

Genzyme Corporation today recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards.

28 Feb 2011

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center and CellSeed Inc., a Japanese biotechnology firm, have entered into a two-year research agreement to study CellSeed's proprietary core technology in regenerative medicine, "Cell Sheet Engineering," LA BioMed President and CEO David I. Meyer, PhD, announced today.

28 Feb 2011

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Omni Bio Pharmaceutical, Inc., an emerging biopharmaceutical company formed to acquire, license, and develop existing therapies for indications with substantial commercialization potential, has committed to expand its Phase I/II human clinical trial in recently diagnosed Type 1 diabetes patients from 15 patients to 50.

28 Feb 2011

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Plexxikon Inc. today announced it has entered into a merger agreement with Daiichi Sankyo Company, Limited, a Japan-based global pharmaceutical company.

28 Feb 2011

Tanning age limits set by American Academy of Pediatrics

The American Academy of Pediatrics is now setting an age limit under which people cannot avail the services at a tanning salon. A salon in the Poconos said they already have strict rules in place. Paradise Tanning in Tannersville and East Stroudsburg have a set of rules they follow when it comes to allowing young people to tan. Most salons agree that preventing under age tanning is the parents’ responsibility.

28 Feb 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Katie Couric to launch new citywide campaign for colon cancer screenings

In honor of National Colon Cancer Awareness Month, Katie Couric, the New York City Department of Health and Mental Hygiene, WCBS-TV and The Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian Hospital will launch the "Make That Call" for colon cancer screening campaign.

28 Feb 2011

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

ACT Biotech, Inc., a biopharmaceutical company focused on the development of highly targeted, oral therapeutics for the treatment of cancer, announced today that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) related to a randomized Phase 3 trial of telatinib in combination with chemotherapy for the first-line treatment of patients with advanced stomach cancer.

28 Feb 2011

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Regeneron Pharmaceuticals, Inc. announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol therapy, ARCALYST (rilonacept) met the primary and all secondary study endpoints. The primary endpoint was the number of gout flares per patient over the 16-week treatment period.

28 Feb 2011

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that it had received a net sales milestone of $2.5 million from Cowen Healthcare Royalty Partners, L.P..

28 Feb 2011

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review classification to its Supplemental New Drug Application (sNDA) regarding ISTODAX (romidepsin) for injection for the treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy.

28 Feb 2011

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 1819698 to Rexahn for its novel anti-cancer quinoxalinyl-piperazine compounds.

28 Feb 2011

Cancer News and Research

Latest Cancer News and Research

Aggressive treatment of T3 and T4 NSCLC with induction chemoradiotherapy may improve survival

Dermatan sulfate holds potential as an additional biomarker for Sanfilippo disease

Despite absence of Medicare coverage, hospital use of CTC is on the rise: Study

HP announces innovative drug research application for its inkjet technology

Researcher identifies substance that inhibits cancer growth by activating 'dark genome'

Cancer drug may help combat flu

Social networking websites can increase risky sexual behaviors in homeless youth: New study

Two genes linked to binge drinking

Genzyme introduces new global grant program to support LSD patient community

CellSeed, LA BioMed enter two-year research agreement to study core technology in regenerative medicine

Omni Bio to expand Type 1 diabetes Phase I/II trial from 15 to 50 patients

Daiichi Sankyo enters merger agreement to acquire Plexxikon

Tanning age limits set by American Academy of Pediatrics

TCD announces first patient treated in its TCD-717 Phase I trial

Katie Couric to launch new citywide campaign for colon cancer screenings

ACT Biotech files SPA with FDA for telatinib combination Phase 3 trial for stomach cancer

Regeneron's ARCALYST meets primary, secondary endpoints in second Phase 3 gout flare study

Aeterna Zentaris receives $2.5M net sales milestone payment from Cowen Royalty

Celgene's ISTODAX sNDA granted FDA Priority Review classification for progressive/relapsed PTCL

Rexahn's novel anti-cancer quinoxalinyl-piperazine compounds granted European patent

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in